1. Armitage (1995) Treatment strategies for patients with relapsed or refractory Hodgkin’s disease (editorial). Ann Oncol 6: 517–518
2. Bargou RC, Emmerich F, Krappmann Detal. (1997) Constitutive nuclear factor-kappaB-ReIA activation is required for proliferation and survival of Hodgkin’s disease tumor cells.J Clin Invest 100: 2961–2869
3. Bergsagel DE, Alison RE, Beau HA et al. (1982) Results of treating Hodgkin’s disease without a policy of laparotomy staging. Cancer Treat Rep 66: 717–731
4. Biti GP, Cimino G, Cartoni C et al. (1992) Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin’s disease: Eight-year update of an Italian prospective randomized study.) Clin Oncol 10: 378–382
5. Bitter MA, Franklin WA, Larson RA et al. (1990) Morphology in Ki-1 (CD30)-positive non-Hodgkin’s lymphoma is correlated with clinical features and the presence of a unique chromosomal abnormality, t(2;5)(p23;g35).Am J Surg Pathol 14: 305–316